Navigation Links
Heparin-like compounds inhibit breast cancer metastasis to bone
Date:5/21/2012

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases and showed that heparin-like compounds can potentially be used to inhibit breast cancer metastasis to bone.

These findings were published on the Molecular Cancer Research journal website on 20th April 2012.

The researchers at VTT used RNA interference-based screening in breast cancer cells and found that an enzyme that modifies heparan sulfate glycosaminoglycans, HS6ST2, is an important regulator of breast cancer cellbone interactions. Heparin, which is commonly used as an anticoagulant, also inhibited this regulatory mechanism.

Experiments in a mouse model of breast cancer bone metastasis indicated that heparin-like compounds decreased bone destruction and tumor growth in bone. One of these heparin-like compounds, developed by Biotie Therapies, has a significantly reduced anticoagulant activity as compared to heparin, which improves its applicability as a potential cancer therapeutic agent.

Breast cancer that has metastasized to bone is currently an incurable disease, causing significant morbidity and mortality.


'/>"/>
Contact: Merja Perl, Principal Scientist
merja.perala@vtt.fi
358-207-222-825
VTT Technical Research Centre of Finland
Source:Eurekalert

Page: 1

Related biology news :

1. Duke team finds compounds that prevent nerve damage
2. Discovery of natural compounds that could slow blood vessel growth
3. New $11 million center to speed production of new compounds for drug discovery
4. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
5. Scripps research scientists identify compounds for stem-cell production from adult cells
6. Two new compounds show promise for eliminating breast cancer tumors
7. 2 new compounds show promise for eliminating breast cancer tumors
8. Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
9. Compounds could be new class of cancer drugs
10. MSU discoveries upend traditional thinking about how plants make certain compounds
11. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global ... a CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Windtree Therapeutics, Inc. ... focusing on developing aerosolized KL4 surfactant therapies for ... preclinical influenza study showed that aerosolized KL4 surfactant ... a well-established preclinical animal model. The Company believes ... body of evidence that supports the role of ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, Slone ... with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive ... focused on identifying inherited disease risk in future generations. In his new role, ...
(Date:2/15/2017)... Inc. (Vanda) (NASDAQ: VNDA), today announced financial and ... year ended December 31, 2016. "2016 ... continued to demonstrate strong growth in our commercial ... Mihael H. Polymeropoulos, M.D., Vanda,s President and CEO. ... milestones underscores Vanda,s commitment to bringing important new ...
(Date:2/15/2017)... ... 2017 , ... Diameter Health (Diameter) and Lantana ... in the hands of Lantana analysts. The high-performance platform of Diameter combined with ... entities – all those mining value from clinical data – to get the ...
Breaking Biology Technology: